Evaluate the implications of single versus multiple device use on implementation of triple therapy in eligible patients with COPD managed in routine care

The primary objective of this study is to evaluate whether a single fixed dose combination (FDC) triple therapy (inhaled corticosteroid & dual bronchodilation) treatment regimen in patients with COPD is associated with better real-life clinical outcomes than use of “free” triple regimens. The study will also evaluate the association between frequency of dosing regimen (e.g. once daily versus twice daily) and clinical outcomes in the real-world management of patients with COPD. Lead Investigator:
Alberto Papi
Research Team:
David Price, Claus Vogelmeier, Marc Miravitlles, Nicolas Roche. Status: Proposed Study, Seeking Funding
Documents and Publications
Final Publications
Additional Material

Leave a Reply

Your email address will not be published. Required fields are marked *